As I discussed previously, not only does any other reformulation of bisantrene need to get around our existing granted reformulation patents, but the reformulation needs to offer clinical benefit over RC220 for it to be even ethical to run a clinical trial. Given what I know about reformulation and bisantrene's mechanism of action I don't think significant clinical improvement can be achieved via a different reformulation that we haven't already patented.
What is far more likely is a fast-follow, me-too drug with the same mechanism of action as bisantrene. Once you know what you want to achieve clinically you can throw a few dozen very talented chemists at the problem and they will develop you a new drug. While nobody can stop this from happening, we do have a plan to make this very, very difficult and time consuming to take any "new bisantrene" to approval.
- Forums
- ASX - By Stock
- RAC
- Cardioprotection thread
Cardioprotection thread, page-783
-
-
- There are more pages in this discussion • 123 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.56 |
Change
0.010(0.65%) |
Mkt cap ! $265.8M |
Open | High | Low | Value | Volume |
$1.55 | $1.56 | $1.51 | $95.69K | 62.25K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 3015 | $1.55 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.56 | 4018 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 3015 | 1.550 |
2 | 17973 | 1.530 |
1 | 19190 | 1.525 |
1 | 20000 | 1.520 |
1 | 500 | 1.500 |
Price($) | Vol. | No. |
---|---|---|
1.560 | 4018 | 1 |
1.570 | 4602 | 2 |
1.580 | 15715 | 3 |
1.600 | 2319 | 1 |
1.645 | 10000 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online